Have a feature idea you'd love to see implemented?
Let us know!
CTMX CytomX Therapeutics Inc
Price (delayed)
$1.075
Market cap
$84.13M
P/E Ratio
6.32
Dividend/share
N/A
EPS
$0.17
Enterprise value
$53.12M
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics,
Highlights
CTMX's equity has surged by 54% year-on-year and by 25% since the previous quarter
CTMX's revenue is up by 34% year-on-year and by 6% since the previous quarter
CTMX's quick ratio is down by 24% year-on-year but it is up by 3% since the previous quarter
Key stats
What are the main financial stats of CTMX
Market
Valuations
Earnings
Shares outstanding
78.26M
Market cap
$84.13M
Enterprise value
$53.12M
Price to earnings (P/E)
6.32
Price to book (P/B)
N/A
Price to sales (P/S)
0.72
EV/EBIT
3.53
EV/EBITDA
2.54
EV/Sales
0.42
Revenue
$126.62M
Gross profit
$126.62M
Net income
$13.83M
EBIT
$15.06M
EBITDA
$20.89M
Free cash flow
-$88.78M
Per share
Balance sheet
Liquidity
EPS
$0.17
EPS diluted
$0.17
Free cash flow per share
-$1.04
Book value per share
-$0.3
Revenue per share
$1.49
TBVPS
$1.61
Total assets
$138.98M
Total liabilities
$162.43M
Debt
$10.6M
Equity
-$23.45M
Working capital
$4.95M
Debt to equity
-0.45
Current ratio
1.04
Quick ratio
1.02
Net debt/EBITDA
-1.48
Margins
Efficiency
Dividend
EBITDA margin
16.5%
Gross margin
100%
Net margin
10.9%
Operating margin
5.3%
Return on assets
8.1%
Return on equity
N/A
Return on invested capital
252.2%
Return on capital employed
76.2%
Return on sales
11.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTMX stock price
How has the CytomX Therapeutics stock price performed over time
Intraday
0.47%
1 week
-2.27%
1 month
5.39%
1 year
-27.36%
YTD
-30.65%
QTD
-8.9%
Financial performance
How have CytomX Therapeutics's revenue and profit performed over time
Revenue
$126.62M
Gross profit
$126.62M
Operating income
$6.71M
Net income
$13.83M
Gross margin
100%
Net margin
10.9%
The operating income has soared by 144% year-on-year and by 17% since the previous quarter
The company's operating margin has surged by 133% YoY and by 10% QoQ
CTMX's revenue is up by 34% year-on-year and by 6% since the previous quarter
The gross profit is up by 34% year-on-year and by 6% since the previous quarter
Growth
What is CytomX Therapeutics's growth rate over time
Valuation
What is CytomX Therapeutics stock price valuation
P/E
6.32
P/B
N/A
P/S
0.72
EV/EBIT
3.53
EV/EBITDA
2.54
EV/Sales
0.42
The EPS has grown by 21% from the previous quarter
CTMX's equity has surged by 54% year-on-year and by 25% since the previous quarter
The stock's P/S is 86% less than its 5-year quarterly average of 5.3 and 35% less than its last 4 quarters average of 1.1
CTMX's revenue is up by 34% year-on-year and by 6% since the previous quarter
Efficiency
How efficient is CytomX Therapeutics business performance
CTMX's return on assets is up by 40% since the previous quarter
The ROS has contracted by 6% from the previous quarter
Dividends
What is CTMX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTMX.
Financial health
How did CytomX Therapeutics financials performed over time
CTMX's total assets is 14% less than its total liabilities
The company's total liabilities fell by 40% YoY and by 15% QoQ
CTMX's total assets is down by 37% YoY and by 13% from the previous quarter
CTMX's debt is 145% greater than its equity
The debt to equity has dropped by 114% year-on-year and by 18% since the previous quarter
CTMX's equity has surged by 54% year-on-year and by 25% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.